Skip to main content
Log in

The US FDA has notified the cystic fibrosis (CF) community about the possible risk of cataract development in children taking ivacaftor [Kalydeco].

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. FDA Food and Drug Administration.FDA Notification to the Cystic Fibrosis Community on Kalydeco (ivacaftor). Internet Document: 29 Aug 2012. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The US FDA has notified the cystic fibrosis (CF) community about the possible risk of cataract development in children taking ivacaftor [Kalydeco].. React. Wkly. 1418, 3 (2012). https://doi.org/10.2165/00128415-201214180-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214180-00010

Keywords

Navigation